Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Impaired and Normal Glucose Tolerance

NCT05468229 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT05468229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05468229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Impaired and Normal Glucose Tolerance
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 31, 2022
Completion date
April 30, 2023
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glucose intolerance